drugset / Trial / NCT00860093

Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy

NCT00860093 ↗

Phase 2 Terminated 135 enrolled Mission Pharmacal
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of MP-5971 in facilitating stone passage after Shock Wave Lithotripsy treatment.

Timeline

Start
2010-04
Primary completion
2010-11
Completion
2010-12

Outcome

Outcome not reported

Stopped (Business): “Sponsor Corporate Business Decision”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MPC-5971 Small molecule 20 meq Oral
Subject MPC-5971 Small molecule 40 meq Oral
Subject MPC-5971 Small molecule 60 meq Oral

Indications